Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to alleged misleading statements and concealment of material facts related to the company's capital allocation and dividend strategy [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Organon & Co. provided overly positive statements to investors while concealing significant adverse facts about its priorities, particularly regarding capital allocation and a debt reduction strategy following the acquisition of Dermavant [3]. - The company reportedly reduced its regular quarterly dividend by 70%, which was not disclosed to investors prior to the announcement [3]. Stock Price Impact - Following the announcement of the dividend cut, Organon's stock price fell from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [3]. Class Action Details - The class period for the lawsuit is defined as October 31, 2024, to April 30, 2025, and shareholders are encouraged to register for participation in the class action [3][4]. - The deadline for shareholders to seek lead plaintiff status is July 22, 2025, and there is no cost or obligation to participate in the case [4]. Firm's Commitment - The Gross Law Firm emphasizes its mission to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements [5].

Those who purchasedNASDAQ: PCRX shares should contact the Shareholders Foundation, Inc. CONTACT: SAN DIEGO, July 16, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Pacira BioSciences, Inc. (NASDAQ: PCRX) shares. Investors who purchased shares of Pacira BioSciences, Inc. prior to August 2023 and continue to hold any of thoseNASDAQ: PCRX shares also have certain options and contact the Shareholders Foundation at [email protected] or call +1(858) ...

Core Viewpoint - The Schall Law Firm is investigating Proficient Auto Logistics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Proficient Auto issued false or misleading statements and failed to disclose relevant information to investors [2]. - Following the announcement of Q1 financial results on May 7, 2025, Proficient Auto reported a decline in year-over-year total operating revenue and a net operating loss [2]. - As a result of the negative financial news, Proficient Auto's shares fell by more than 4.9% the following day [2]. Group 2: Legal Representation - The Schall Law Firm offers free consultations for shareholders who may have suffered losses due to the company's actions [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].

Group 1 - The Schall Law Firm is investigating claims on behalf of investors of BellRing Brands, Inc. for potential violations of securities laws [1] - The investigation centers on whether BellRing made false or misleading statements and failed to disclose important information to investors [2] - During its Q2 earnings call on May 6, 2026, BellRing announced that Q3 sales growth would slow to "low-single-digits" due to customers optimizing inventories, leading to a nearly 19% drop in shares on the same day [2]

LOS ANGELES, July 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Laser Photonics Corporation ("Laser Photonics" or "the Company") (NASDAQ: LASE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Laser Photonics disclosed in a May 29, 2025, SEC filing that ...

LOS ANGELES, July 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of KBR, Inc. ("KBR" or "the Company") (NYSE: KBR) for violations of the securities laws. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335 [email protected] www.schallfirm.com The investigation focus ...

Core Viewpoint - The Schall Law Firm is investigating Centene Corporation for potential violations of securities laws, particularly regarding misleading statements and undisclosed information that may have affected investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Centene issued false or misleading statements and failed to disclose critical information to investors [2]. - A Seeking Alpha report indicated that Centene's shares declined after the company withdrew its 2025 earnings guidance, citing higher-than-expected costs related to Medicaid enrollees and underperformance in its Affordable Care Act plans [2]. - Following the announcement, Centene's shares fell by more than 39.5% during intraday trading on the same day [2]. Group 2: Company Background - Centene Corporation is involved in providing healthcare services, particularly through Medicaid and Affordable Care Act plans [2]. - The company reported a significant increase in medical cost trends in areas such as behavioral health, home health, and high-cost drugs [2].

Core Viewpoint - Rowley Law PLLC is investigating potential securities law violations related to the proposed acquisition of Veritex Holdings, Inc. by Huntington Bancshares Incorporated, which is valued at approximately $1.9 billion [1]. Group 1: Acquisition Details - The proposed acquisition involves stockholders of Veritex Holdings receiving 1.95 shares of Huntington Bancshares common stock for each share of Veritex Holdings stock they hold [1]. - The transaction is expected to close in the fourth quarter of 2025 [1]. Group 2: Legal Investigation - Rowley Law PLLC is representing shareholders in the investigation concerning the acquisition and potential securities law violations by Veritex Holdings and its board of directors [1]. - Additional information regarding the investigation can be obtained by contacting Rowley Law PLLC [2].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Reckitt Benckiser Group plc regarding a class action lawsuit related to misleading statements and omissions concerning the safety of its Enfamil formula for preterm infants [1][3]. Group 1: Allegations and Class Period - The class period for the lawsuit is defined as January 13, 2021, to July 28, 2024 [3]. - Allegations include that Reckitt's cow's milk-based formula, Enfamil, posed an increased risk of necrotizing enterocolitis (NEC) in preterm infants, which was not disclosed [3]. - The lawsuit claims that Reckitt's positive statements about its business and operations were materially false and misleading due to the undisclosed risks and potential legal claims [3]. Group 2: Shareholder Actions and Deadlines - Shareholders are encouraged to register for the class action by August 4, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights who have suffered losses due to deceit and illegal business practices [5]. - The firm emphasizes the importance of responsible business practices and corporate citizenship [5]. - The firm seeks recovery for investors affected by misleading statements that led to artificial inflation of the company's stock [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its lead product candidate, PGN-EDO51, and its clinical study, CONNECT2 [1][2]. Allegations - The lawsuit claims that during the class period from March 7, 2024, to March 3, 2025, PepGen misrepresented the effectiveness and safety of PGN-EDO51 [1]. - It is alleged that the CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study [1]. - The complaint states that the clinical, regulatory, and commercial prospects of PGN-EDO51 were overstated, making the company's public statements materially false and misleading [1]. Class Action Details - Shareholders who purchased shares of PepGen during the specified class period are encouraged to register for the class action by August 8, 2025 [2]. - Registration allows shareholders to receive updates on the case and does not incur any costs or obligations [2]. Law Firm Background - The Gross Law Firm is recognized for its commitment to protecting investors' rights against deceit and fraud, aiming to hold companies accountable for misleading practices [3].